Zou Bin
Founder & Chief Executive Officer Axcynsis
Bin Zou is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at National University of Singapore. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into investigational new drug (IND) stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications. Zou Bin holds a Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences and graduated with a B.S in Chemistry from Nankai University.
Seminars
- Evaluating the value of payloads beyond Tubulin and Topoisomerases and why novel payload approaches will hold potential to overcome drug resistance
- What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success
- Specifically thinking about DACs, what is it about small molecule degraders that lend themselves to making good payloads?
- Discussing the panelists approach to business development. What would a win/win business deal look like that focuses on payloads?
